Lineage Cell Therapeutics (LCTX) Retained Earnings (2010 - 2026)

Lineage Cell Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$471.8 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 17498.28% year-over-year to -$471.8 million in Q1 2026; TTM through Mar 2026 was -$471.8 million, a 17498.28% decrease from a year earlier, with the FY2025 full-year figure at -$3.9 million, down 36.3% from the prior year.
• Retained Earnings slipped to -$471.8 million in Q1 2026 per LCTX's latest filing, from -$3.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$2.7 million in Q1 2025 and bottomed at -$471.8 million in Q1 2026.
• The 5-year median for Retained Earnings is -$363.4 million (2022), against an average of -$253.3 million.
• Across the five-year window, Retained Earnings surged 99.25% in 2024 and plunged 17498.28% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$363.4 million in 2022, then fell by 5.91% to -$384.9 million in 2023, then jumped by 99.25% to -$2.9 million in 2024, then plunged by 36.3% to -$3.9 million in 2025, then sank by 11935.97% to -$471.8 million in 2026.
• Per Business Quant, the three latest LCTX Retained Earnings figures stand at -$471.8 million (Q1 2026), -$3.9 million (Q4 2025), and -$4.3 million (Q3 2025).